Other languages CanSino Biologics Inc. Shanghai S.E.

Equities

688185

CNE100004BM0

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
52.07 ^CNY	+0.06%		-2.27%	-30.13%

29/04	CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/04	Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	22/04
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02
Cansino Biologics Inc. Announces Board and Committee Elections	23/02
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
CanSino Biologics Deconsolidates CanSino SPH	02/02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31/01
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01
AstraZeneca comprará la china Gracell Biotechnologies en una operación de 1.200 millones de dólares	26/12
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/12
Scientists see risk of lost opportunity for long COVID research in China	14/12
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	06/12
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	03/12
CanSino Biologics CFO Steps Down	17/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 03:38 pm IST